MYD88 and myeloid sarcoma: TLR/MyD88 as a therapeutic target. Previous studies have demonstrated the involvement of TLRs in the pathogenesis of MS, rendering TLR-MyD88-targeted immunotherapy a potential approach for the treatment of MS and other inflammatory diseases.